La maladie de Behçet: étude clinique de 39 observations. Discussion des critères diagnostiques
D. Vital Durand(Hôpital Lyon Sud), R Levrat(Hôpital Lyon Sud), Béatrice Bocquet(Hôpital Lyon Sud), J. Ninet(Hospices Civils de Lyon), P. Combemale(Centre Léon Bérard), G Llorca(Hôpital Lyon Sud), Michel Bouvier(Institute for Research in Immunology and Cancer), Christian Massot(Hôpital Lyon Sud), J. Pasquier(Hôpital Lyon Sud), J Jeanneret(Hôpital Lyon Sud), D Mennecier(Hôpital Lyon Sud)
Cited by 0
Related Papers
Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants
|Journal of Clinical Investigation|2000|561
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
|British Journal of Dermatology|2019|197
Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement
|Cytogenetics and Cell Genetics|2008|194
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
|Journal of the European Academy of Dermatology and Venereology|2017|192